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osting by EAbstract Clinical Pharmacy is a unique service provided by the leading pharmacy departments in
the United States. The concept of Clinical Pharmacy evolved after the signiﬁcant increase in number
of pharmaceuticals in the market and the increasing potential of drug interactions. However, the
Clinical Pharmacist is not merely an individual who advises on drug interactions. There are a num-
ber of functions which include but are not limited to; the design of appropriate drug therapy, such
as Pharmacokinetic assessment and evaluation to optimize drug therapy, drug information dissem-
ination to the physicians and other healthcare providers and participation as a toxicology consul-
tant in Poison management.
At the King Khalid University Hospital (KKUH) the ﬁrst Clinical Pharmacy services program
began in 1983. The aim of this study is to evaluate the impact of our Clinical Pharmacy program
on the patients’ care as well as its perception by the Medical staff that came from different parts of
the world.
Our Clinical Pharmacists were asked to record any suggestions or interventions in the form. The
forms were all collected at the end of each day and entered into a database for analysis. Each interven-
tion was analyzed in order to assess the merit of the action in terms of the therapeutic, ﬁnancial and
direct cost impact.
The study showed a positive impact on the patients’ care as well as on the economy of the drugs pre-
scribed.Meanwhile, the servicewas verymuch appreciated by theMedical staff aswell as other health-
care providers.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved..com
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274 A.A. Saddique1. Introduction
The pharmacy department at KKUH was the ﬁrst pharmacy
department to implement the Clinical Pharmacy program out-
side the Continental USA. This unique service was established
in 1983 with one clinical pharmacist, following which ﬁfteen
Clinical Pharmacists were recruited after the initial trial and
the service was expanded to cover all hospital Clinical disci-
plines. During the initial period of implementation the service
was assessed using a questionnaire sent to each physician and
nurse for their opinions of Clinical Pharmacists who provide
services for their respective areas. This method is biased and
does not give an accurate depiction of the services provided
by Clinical Pharmacists but rather a personal judgment of an
individual.
The clinicians practicing at this institution came from all
corners of the globe and most have little or no experience in
working with Clinical Pharmacists. Meanwhile, the adminis-
trators at KKUH are not familiar with what a clinical pharma-
cist is capable of achieving in terms of both ﬁnancial savings
for the hospital as well as therapeutic beneﬁts for the patients.
The purpose of this study was to determine what services
Clinical Pharmacists are providing, how they are providing
them, and the overall quality of these services. Quantiﬁcation
of the information was a priority in order to assure thorough,
non-biased results. The information collected is to help us
answer the following questions:
 What is the most frequent type of Clinical Pharmacy
interaction?
 Who is the primary initiator of the intervention?
 Were the recommendations provided by the Clinical Phar-
macists usually accepted, modiﬁed, or ignored?
 What time of the day do most interventions occur and how
much time is spent on each intervention?
 Of the interventions taking place what percentage is thera-
peutically beneﬁcial, have no therapeutic beneﬁt or is detri-
mental to the patient?
 What is the impact of the intervention on immediate direct
costs to the health care system?
 What is the long term ﬁnancial impact of the intervention of
the health care system?
2. Methodology
Seven Clinical Pharmacists and two Clinical Pharmacy resi-
dents were involved in collecting data for the study over a three
month period. Each one was asked to record any suggestions
or interventions on a form provided (Fig. 1). The forms were
all collected at the end of each day and entered into a database
computer program for analysis. Most of the information on
the form was self explanatory, and did not require any inter-
pretation. Each intervention was analyzed in order to assess
the merit of the action in terms of the therapeutic, ﬁnancial
and direct cost impact.
A suggestion was considered therapeutically positive if it
met with the standard of practice for the particular case.
For example, adjusting non-therapeutic or toxic Aminoglyco-
side levels appropriately was considered therapeutically
positive.The ﬁnancial impact was based on the long-term effect of
the intervention. For example in the above case the interven-
tion would be classiﬁed as ﬁnancially positive since optimizing
the dose will lead to a more rapid recovery and hence shorten
the length of hospitalization. If an inappropriate suggestion
had been made this may lead to unnecessarily prolonged hos-
pitalization and increased cost to the health care system.
Direct cost was deﬁned as the immediate effect of the inter-
vention on the health care system regardless of the long-term
ﬁnancial impact. For example if a clinical pharmacist re-
quested an Aminoglycoside serum concentration determina-
tion, this will result in increased direct costs, although the
concentration may be sub therapeutic and necessitate subse-
quent dosage modiﬁcation.
All interventions were analyzed by three Clinical Phar-
macists until a consensus was reached concerning the im-
pact of the intervention. Each intervention was designated
as either positive, negative, or having no effect on the ther-
apeutic, long-term ﬁnancial and direct cost criteria deﬁned
above.
3. Results
A total of 8796 interventions were documented during the
three month period (ﬁve working days a week). Interventions
occurred throughout the hospital encompassing 28 wards
(including all intensive care units), IV pharmacy, Drug and
Poison information Center (DPIC), outpatient pharmacy,
non hospital related clinics, hospital related clinics and in the
homes of several Clinical Pharmacists. The DPIC had the most
number of documented interventions with 900 interventions.
Therapeutic and dosing administration interventions were
the most frequently encountered and accounted for nearly
60% of all interventions, followed by Pharmacokinetic and to-
tal parenteral nutrition interventions, which accounted for 9%
and 9.5% of interventions, respectively. Availability, supply,
and miscellaneous interventions accounted for approximately
6% of interventions each. Side effects, adverse drug reactions,
educational, pregnancy and lactation, interactions and com-
patibility, and poisoning interventions accounted for less than
5% each of the total interventions.
Of all interventions, Clinical Pharmacists initiated 43%,
physicians 42%, nursing staff 5.5%, satellite pharmacists
5.4% and other personnel 4.1%. 86% of the suggestions made
by Clinical Pharmacists were accepted and only 2% modiﬁed
and 3% ignored. Nine percentage of interventions did not pro-
duce a suggestion that required acceptance; hence these were
labeled as not applicable.
Analysis of the therapeutic merit of the interventions shows
that 90% of the interventions had a positive therapeutic im-
pact while 9% had no therapeutic impact and 1% had a neg-
ative impact.
Immediate direct costs increased due to the intervention in
27%of the cases.No effect on direct cost and a decrease in direct
costs were seen in 50% and 23% of the cases, respectively.
Long term ﬁnancial impact of the interventions was posi-
tive (reduce healthcare costs) in 96% of the cases, increased
in 1% and had no effect in 3%.
The average time involved by a clinical pharmacist was
9.59 min per interventions with a range of 1–240 min. The time
of the day in which most interventions occurred was 10 am
Figure 1 Form used by the Clinical Pharmacists to document interventions.
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administration and dosage interventions was 5.4 min (range 1–
45 min), for availability 4.6 min (range 1–14 min), for thera-
peutic interventions 6.69 min (range 1–90 min), for side effects
and adverse drug reactions 11.2 min (range 2–60 min), for
pregnancy and lactation interventions 7.1 min (range 1–
60 min), for Pharmacokinetic interventions 8.14 min (range
1–30 min), for educational 46.77 min (range 2–240 min), for
total parenteral nutrition 13.03 min (range 1–45 min), for Poi-
soning interventions 23 min (range 5–30 min), and for other
21.33 min (range 1–180 min).Table 1 The average time taken by Clinical Pharmacists for
various interventions.
Intervention Average time (min) Range (min)
Administration and dosage 5.4 1–45
Availability 4.6 1–14
Therapeutic 6.69 1–90
Side eﬀects and ADR 11.2 2–60
Pregnancy and lactation 7.1 2–20
Interaction and compatibility 14.5 1–60
Pharmacokinetics 8.14 1–30
Educational 46.77 2–240
Total parenteral nutrition 13.03 1–45
Poisoning 23.0 5–30
Other 21.33 1–1804. Discussion
The unique feature of this study is the material itself since no
one in this institution has ever attempted to actually document
all the interventions of the Clinical Pharmacy staff over a per-
iod of time. After reviewing the data, it was clear that Clinical
Pharmacists were not just attending rounds and making pas-
sive suggestions. They were actively involved in the decision
making process on a prospective basis. The clinical staff were
involved throughout the entire hospital and not just the in the
wards in which they were assigned. The drug information ser-
vice handled 900 interventions in a three month period plus the
regular ward assignments for the employees. Clinical Pharma-
cists were also contacted at home several times in the manage-
ment of poisonings.
After calculating the time involved per intervention as an
average one sees that a clinical pharmacist is a very efﬁcient
decision-maker both in terms of therapeutics and in minimiz-
ing cost. Although the response time for the questions varied
considerably based on the type of questions (Table 1).
Therapeutic interventions, administration, and dosage ac-
counted for a majority of the interventions. This is an impres-
sive statistic since these are exactly what is expected of Clinical
Pharmacists. The therapeutic, dosing, and administration
interventions were the most signiﬁcant interactions. Recom-
mendations of Clinical Pharmacists involved prolonging, dis-
continuing, or modifying (i.e. adding or deleting drugs from
a regimen) therapy, adjusting dosages and evaluating treat-
ment outcome.
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the third most frequent type of interventions. This shows that
Clinical Pharmacists play a major role in managing patients on
parenteral nutrition which is advantageous for the patient and
the pharmacy services. A clinical pharmacist has extensive
training in this area and hence can provide a unique service
that maximizes beneﬁt to the patient and at the same time,
with a thorough understanding of drug delivery and cost anal-
ysis procedures, can minimize cost.
Pharmacokinetic intervention came in the fourth most fre-
quent intervention. Clinical Pharmacists are known as the
pharmacokinetic experts within the hospital and hence are
the only members of the healthcare team who are trained to
provide this information. The interventions not only included
adjustment of patients’ dose but also request for drug levels to
assess therapy.
An interesting role of the clinical pharmacist is the one of
inventory analysis. Availability and supply intervention were
the ﬁfth most common. This is possibly the result of daily vari-
ations in inventory. Maintaining a constant supply of a drug is
almost impossible at our institution, due to the signiﬁcant var-
iation in consumption based on the practitioners’ background.
The clinical pharmacist is continually bombarded by questions
of availability and supply and hence is a link between the
clinician and the stores.
Other interventions included work on research, reviewing
material for the pharmacy and therapeutic committee, attend-
ing committee meetings etc.
Interventions on side effects and on interactions and com-
patibility combined account for about 5% of interventions.
These were questions, which required some research to be done
by Clinical Pharmacists in order to provide the physician with
literature on a particular adverse reaction or side effect. Inter-
actions and compatibility interventions were primarily associ-
ated with administration of several drugs or IV ﬂuids
throughout the same line. Clinical Pharmacists are the only
members of the healthcare team who have extensive training
in this ﬁeld and whenever a situation such as this arises a clin-
ical pharmacist’s opinion is always sought.
Pregnancy and lactation interventions were restricted to the
drug information services. These interventions were all con-
cerning the use of a certain drug during pregnancy or lactation.
The drug and poison information center is known throughout
the entire hospital and university for its ability to provide an-
swers reliably and quickly to difﬁcult questions such as these.
The primary shortcoming of this investigation is the lack of
a method to calculate the long-term ﬁnancial impact of an
intervention. The long-term impact of the intervention is of pri-
mary importance in assessing how much money is saved
through the actions of Clinical Pharmacists. Some suggestions
may result in an immediate saving as the one that leads to a pa-
tient’s discharge on an earlier date due to an intervention by the
clinical pharmacist. The Clinical Pharmacists were able to re-
duce both immediate and long term expenditures by discon-
tinuing medications that were of no therapeutic beneﬁt or
were producing adverse reactions. Unfortunately, we have no
ﬁgures to estimate the savings that are realized by the use of
Clinical Pharmacists in this institution. Other centers have doc-
umented major reductions in costs by implementing Clinical
Pharmacy programs (Marie et al., 2008; Jennifer et al., 2011;
Chisholm et al., 2001; Viktil and Blix, 2008; Weant et al.,2009; Schumock et al., 2003). However, most of these studies
addressed one activity of Clinical Pharmacy Services, e.g. Dia-
betes, Hyperlipidemia, drug related problems etc.
Healthcare today requires not only the knowledge of path-
ophysiology, therapeutics and pharmacology but also econom-
ics. Healthcare costs continue to rise world-wide resulting in an
increased necessity to minimize cost while maximizing thera-
peutic beneﬁt. This is speciﬁcally pertinent in teaching institu-
tions for two basic reasons. First, many of the junior medical
staff has absolutely no knowledge of drug cost. With the aid of
Clinical Pharmacists, they can learn to prescribe a less expen-
sive agent without compromising the health of the patient. Sec-
ondly, the junior medical staff will be the senior staff of
tomorrow. They must understand proper prescribing in order
to limit the healthcare expenditures of the future. Clinical
Pharmacists are unique members of the healthcare team for
not only are they aware of proper drug utilization in all ﬁelds
of medicine but are especially aware of drug costs. Clinical
Pharmacists offer a new approach to maximizing healthcare
delivery and at the same time in reducing costs.
5. Conclusion
This study provides evidence of the economic value of Clinical
Pharmacy services, and the appreciation of the Medical staff of
this unique service. However, in our country Clinical Phar-
macy is not fully appreciated at the government level i.e. Min-
istry of Health Hospitals. The main Hospitals that utilize
Clinical Pharmacists are the Specialty Hospitals, University
Hospitals, and other elite Medical Centers. The Saudi Pharma-
ceutical Society has a role to play in promoting the image of
Clinical Pharmacy and to educate the executive members of
the Ministry of Health of the value of Clinical Pharmacists
and their impact on cost saving in an escalating cost of Health-
care provision. Clinical Pharmacists should be encouraged to
engage in direct patient’s care services not to be given admin-
istrative positions where their impact on the healthcare quality
and development is not noticed nor appreciated. Once the
Pharmaceutical services in the country are fully developed
and the standards of Pharmacy practice are set and executed
then Clinical Pharmacists can move into administrative posi-
tions. More comprehensive studies on the role of Clinical
Pharmacists need to be carried out and published, this study
is the ﬁrst of its kind in the Kingdom and we are aware of
the limitations of this study, however, it is just a start and
the future will demonstrate the value and the beneﬁts of
involving Clinical Pharmacists and the Clinically oriented
Pharmacists in immediate patient’s care.References
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